Publication Date:
2012-11-16
Description:
Abstract 4358 Objective Warfarin is an oral vitamin K antagonist commonly used in pediatric patients who require anticoagulation. Studies in adults receiving warfarin demonstrate that polymorphisms in 2 genes involved in warfarin disposition and response, cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex, subunit 1 (VKORC1), explain 30–40% of the variation in stable dose. Recent evidence suggests a role for a cytochrome P450 4F2 (CYP4F2) variant in altered warfarin disposition. These associations have not been well-studied in the pediatric population. We hypothesized that polymorphic variants in CYP2C9, VKORC1, and CYP4F2 are associated with interindividual variability in stable warfarin dose in pediatric patients. Methods We designed a cross-sectional study examining the relationship between stable warfarin dose and commonly occurring polymorphisms in CYP2C9 (*2 and *3), VKORC1 (haplotype A, comprised of 5 promoter and intronic variants), and CYP4F2 (variant allele T) in children. Patients
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine